Immunomedics Inc. (IMMU) Drops 10.7% on January 11

Equities Staff |

Immunomedics Inc. (IMMU) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 10.7% to $2.05, a loss of $-0.245 per share. Starting at an opening price of $2.32 a share, the stock traded between $2.04 and $2.40 over the course of the trading day. Volume was 1.19 million shares over 6,058 trades, against an average daily volume of 852,860 shares and a total float of 94.64 million.

The losses send Immunomedics Inc. down to a market cap of $193.54 million. In the last year, Immunomedics Inc. has traded between $5.48 and $1.50, and its 50-day SMA is currently $3.02 and 200-day SMA is $3.14.

Immunomedics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Immunomedics Inc. is based out of Morris Plains, NJ and has some 123 employees. Its CEO is Cynthia L. Sullivan.

For a complete fundamental analysis analysis of Immunomedics Inc., check out Equities.com’s Stock Valuation Analysis report for IMMU. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Veritas Pharma Inc.

Veritas Pharma Inc, formerly Seashore Organic Medicine Inc is an emerging producer and distributor of medical marijuana.

Private Markets

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…

WayBetter

The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…